SGS outlines long-term growth strategy, shares tracked against testing peers

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-23, 09:43.

SGS (CH0002497458) continues to position itself as a core holding in the global testing, inspection and certification universe. The Swiss group, listed on SIX Swiss Exchange, is benchmarked closely against Eurofins Scientific and Intertek when investors assess long-term growth and margins.

How SGS grows in TIC

SGS focuses on recurring revenue from testing and inspection contracts across industries such as commodities, industrial manufacturing and consumer products, which together represent a multi-billion Swiss franc addressable market according to company disclosures.

The group also targets bolt-on acquisitions in specialized niches like materials testing and life sciences laboratories to expand its geographic footprint and deepen sector expertise, a strategy highlighted in its recent investor presentations.

Strategy in a global peer context

In the broader testing sector, Eurofins Scientific and Intertek pursue similar asset-light, service-based models, which helps investors compare SGS on metrics such as organic growth, EBIT margin and cash conversion.

Analyst commentary on listed peers underlines that recurring contracts, regulatory-driven demand and high client switching costs support relatively resilient cash flows across the sector, an important reference point for the SGS stock.

How SGS makes its money

SGS generates revenue by providing laboratory testing, on-site inspection and certification services, for example for consumer goods safety, industrial equipment compliance and commodities quality assurance, with fees typically charged per test, project or contract period.

Where the stock trades today

The SGS shares (CH0002497458) trade on the SIX Swiss Exchange in Zurich, with the latest available quotes published in Swiss francs on the exchange-operated price pages.

This text is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities.